EPZ-5676 was also found to act synergistically with cytarabine, daunorubicin, and the DNMT inhibitor azacitidine, three common AML standard care drugs, in the human acute leukemia cell lines MOLM-13 (MLL-AF9) and MV4-11 (MLL-AF4) [80]. This evidence concerns the gene KMT2A and acute leukemia.